Literature DB >> 1079422

Protease inhibitors in chronic obstructive pulmonary disease.

T B Barnett, D Gottovi, A M Johnson.   

Abstract

Quantification of the major plasma protease inhibitors and genetic typing of alpha1-antirypsin were done in 107 patients with chronic obstructive pulmonary disease and in 91 control subjects with normal ventilatory function who were similar with respect to age, race, and sex. There was a significant increase in frequency of the PiZ gene and the Pi MZ phenotype of alpha1-antitrypsin among the patients when compared with the control subjects. No evidence for a primary deficiency of any other antiprotease was found; however, the mean concentration of inter-alpha-trypsin inhibitor was significantly lower in the patients than the control subjects, and moderate deficiency of alpha1-antichymotrypsin was noted in a few patients. These data indicate an increased risk of developing chronic obstructive pulmonary disease in persons with the Pi MZ phenotype of alpha1-antirypsin and suggest a possible relationship between these diseases and low serum concentrations of inter-alpha-trypsin inhibitor.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079422     DOI: 10.1164/arrd.1975.111.5.587

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

1.  Reference distributions for the positive acute phase proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a comparison of a large cohort to the world's literature.

Authors:  R F Ritchie; G E Palomaki; L M Neveux; O Navolotskaia
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Polymorphism of alpha1-antitrypsin in a Portuguese population.

Authors:  H M Geada; J A Albino; C Manso
Journal:  Hum Genet       Date:  1976-05-19       Impact factor: 4.132

3.  Pulmonary abnormalities in intermediate alpha-1-antitrypsin deficiency.

Authors:  W J Hall; R W Hyde; R H Schwartz; G S Mudholkar; D R Webb; Y P Chaubey; P L Townes
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

4.  Protease inhibitor profile of black Americans with and without chronic cardiopulmonary disease.

Authors:  R C Young; V E Headings; A L Henderson; S Bose; R L Hackney
Journal:  J Natl Med Assoc       Date:  1978-11       Impact factor: 1.798

5.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

6.  Pulmonary emphysema associated with the FZ alpha 1-antitrypsin phenotype.

Authors:  D W Cockcroft; R K Tennent; S L Horne
Journal:  Can Med Assoc J       Date:  1981-03-15       Impact factor: 8.262

Review 7.  Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population.

Authors:  R B Cole; N C Nevin; G Blundell; J D Merrett; J R McDonald; W P Johnston
Journal:  Thorax       Date:  1976-04       Impact factor: 9.139

Review 8.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

9.  Serum and sputum alpha 2 macroglobulin in patients with chronic obstructive airways disease.

Authors:  D Burnett; R A Stockley
Journal:  Thorax       Date:  1981-07       Impact factor: 9.139

Review 10.  Reference distributions for alpha2-macroglobulin: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.